anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A group of phytochemical compounds extracted from whole germinated or not germinated black beans ( Phaseolus vulgaris  L) and/or their dry milled fractions such as seed coats or hulls and cotyledons is described. These phytochemicals are classified as phenolics, such as polyphenols, flavonoids, coumarins, and tannins, triterpenes such as saponins, phytosterols and other antioxidant compounds that proved to be effective to decrease cancer proliferation of hormone dependent mammary (MCF-7), hormone independent hepatic (HepG2) and colon (Caco2) cancer cells. They also effectively protect against chemical damage induced with DMBA and furthermore prevented cancer induced by this chemical in Wistar rats and also reduced tumor size when consumed after tumor detection. Methanol, acetone, ethanol, water and mixtures of these solvents were used to obtain the extracts from raw, cooked, and germinated black beans of different varieties, both from the whole grain and the hulls. The black bean malting process produced extracts rich in aglycone forms of the previous mentioned compounds that were more biologically active against MCF-7 cancer cell proliferation. Both raw extracts, C-18 HPLC refined extracts and fractionated extracts may be used in the treatment, prophylaxis, amelioration or defense against a variety of hormone dependent and independent cancers. The extracts and compounds have additional utilities, e.g., lower cholesterol or lower oxidation of LDL and/or inhibit cholesterol synthesis (or the enzyme therefor) and/or reduce liver fibrosis and/or reduce symptoms of menopause and/or stimulate calcium absorption and/or have estrogenic activity such as feminizing estrogenic activity and/or are antioxidants, for instance, as an active ingredient in a nutritional supplement and/or as a food, cosmetic or pharmaceutical antioxidants or colorants.
This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
FIELD: medicine. SUBSTANCE: method involves obtaining extra overall effect in treating the cases of bronchial asthma by carrying out concurrent treatment of dysbacteriosis considering that the cases of combined occurrence of these two diseases are not seldom. Bronchial asthma exacerbation is often provoked by infectious process in digestive tract system (in biliary ducts, colon, e.t.c.). The method involves achieving physiological desensitization of organism contributing to increasing remission periods as a result of microbiocenosis correction in colon on the background of supporting inhalation treatment with broncholytic preparations with hormone preparations completely excluded from the therapeutic treatment. EFFECT: enhanced effectiveness of treatment. 2 tbl
The invention belongs to the technical field of biology, and particularly relates to application of F1/F3 polypeptide in preparation of medicines for inducing tumor cell apoptosis. The invention proves for the first time that the natural polypeptide F1 polypeptide, F3 polypeptide or modified F1 polypeptide can induce the scorching of tumor cells by activating the Caspase 3/GSDME pathway: when the tumor cells die, the cell membrane swells into a bubble, which then ruptures, secreting large amounts of interleukin 18 and LDH. And when F1 and F3 are combined, the effect is optimal. Experiments prove that the secretion amount of IL18 is in a time-dose dependent relationship. And the tumor cells are epithelial tumor cells, including cervical cancer cell line Hela cells, lung cancer A549 cells, liver cancer Huh-7 cells and the like. The invention further explores the mechanism of the natural polypeptide for preparing the tumor treating medicine, and lays a solid foundation for further expanding the application range of the natural polypeptide.
Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-20 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist. For initial learning of the tablet's basic use, an individual session for each participant will take place.
Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
Disclosed is the preparation of a capsaicin-vitamin E prodrug self-assembled nano drug delivery system, which uses dithiodiglycolic acid to link capsaicin to vitamin E to prepare a capsaicin-vitamin E prodrug (Cap-SVE). On this basis, capsaicin-vitamin E prodrug self-assembled nanoparticles (Cap-SVE NPs) are further prepared. The prodrug self-assembled nanoparticles have some characteristics: the average particle size of less than 200 nm, being near-spherical and uniformly distributed, and the drug loading capacity calculated with capsaicin of up to 8 mg·mL-1. It is stable under acidic conditions and gradually hydrolyzes at pH 7.4. The prodrug self-assembled nanoparticles can reduce the irritation of capsaicin on the gastrointestinal tract, significantly increase the bioavailability of capsaicin, increase the targeting effect of capsaicin in the liver, and significantly improve the anti-oxidative and hypolipidemic efficacy of capsaicin. It has good stability, high safety, and a large market prospect.
Dehalogenation of cpd. of formula (II) yields 2-aminocarboxylic acid derivs. of formula (I), where Hal is halogen m is 0 or 1 W is N of CH R is H or 1-3C alkoxy, and R6, R7 and R8 can be various radicals. - Dehalogenation is effected by treatment with catalytically activated hydrogen at 1-5 bars pressure and 0-75 deg.C in an inert solvent. The prods. are synthesis intermediates and have a hypolipidaemic effect.
Numerous studies have reported that patients with coronavirus disease 2019 (COVID-19) experience alterations in the sense of smell. Therefore, there is an increased need for a psychophysical evaluation tool for olfactory dysfunction in patients with COVID-19 without increasing the risk of virus spread. We applied a single-use sniffing-bead system, which consisted of small beads and a disposable plastic handpiece, to patients with COVID-19 presenting with olfactory dysfunction. The bead sets contained eight concentrations of 2-phenylethyl alcohol (PEA), which has been used in olfactory function tests for many years, and the lowest concentration at which the participant detected the PEA odor was recorded as the PEA threshold. The test was easily administered at the clinic during the consultation with the doctor without increasing the risk of virus spread. Based on the test results, anosmia was objectively confirmed in a patient with subjective anosmia, and another patient with subjective hyposmia was diagnosed with normosmia. Both patients started olfactory training after diagnosis. In conclusion, we present a system to psychophysically assess olfactory dysfunction in patients with COVID-19 using a universal odorant without the risk of virus spread, and suggest that this system might enable early diagnosis and management of patients with COVID-19.
Hearing voices groups (HVGs) are an alternative way of treating acoustic-verbal hallucinations. Although they have been developing in France for the last decade, they have lagged behind their international expansion. The representations that circulate about their functioning and their effects are likely to influence the referral to these groups by mental health professionals. We created and used a questionnaire to survey mental health professionals' representations of voice hearing groups. We surveyed 79 French health professionals using a questionnaire with 19 closed items. 7 additional items allowed us to specify the professional status and familiarity of the participants with the HVGs. Professionals generally shared positive representations of HVGs but had very approximate knowledge of them. The subgroup of the most familiar professionals (N = 45) differed significantly on 7 items from the subgroup of non-familiars (N = 35). HVGs are represented as one medical offer among others, of little clinical use and indicated only for psychotic voice-hearing patients, which seems to be a misunderstanding in every case. However, our study also shows that these opinions evolve with the degree of familiarity with HVGs. Certain representations need to be corrected so that quality information can be circulated about HVGs and improve their integration into their ecosystem.
Allo-HSCT appears to be an efficient tool to cure patients with MDS and AML secondary to MDS. At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing allo-HSCT remains in discussion. BUCY conditioning regimen is the standard myeloablative regimen for MDS and AML secondary to MDS undergoing allo-HSCT. However, it appears to have higher relapse rate. To reduce the relapse rate, decitabine is added in the conditioning regimen. In this prospective randomized controlled study, the safety and efficacy of G-CSF + Decitabine + BUCY and BUCY myeloablative conditioning regimens in RAEB-1, REAB-2 and AML secondary to MDS undergoing allo-HSCT are evaluated.
Rare genetic diseases with neurodevelopmental disorders (NDDs) encompass several heterogeneous conditions (autism spectrum disorder (ASD), intellectual disability (ID), attention deficit hyperactivity disorder (ADHD), specific learning disorder (SLD), among others). Currently, few treatments are available for these patients. The difficulty in accessing human brain samples and the discrepancies between human and animal models highlight the need for new research approaches. One promising approach is the use of the cerebral organoids. These 3D, self-organized structures, generated from induced pluripotent stem cells (iPSCs), enable the reproduction of the stages of human brain development, from the proliferation of neural stem cells to their differentiation into neurons, oligodentrocytes, and astrocytes. Cerebral organoids hold great promise in understanding brain development and in the search for treatments.
After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
Based on the need to improve front-line therapy for patients less likely to undergo transplant, the promising recent in vitro and clinical work on melphalan and bortezomib, we propose a prospective trial with bortezomib added to standard melphalan and prednisone therapy for previously untreated patients with multiple myeloma. Bortezomib 1.3 mg/m2 will be given twice weekly for two weeks and will be added to standard melphalan and prednisone on a 4-week cycle. This three-drug combination will be compared to historical data. We have treated 2 patients with relapsed disease following \>2 prior regimens including high-dose therapy with autologous stem cell support. Each patient received melphalan, prednisone, and bortezomib as described below and both had marked declines in M-protein within 2 cycles. These responses have been sustained for at least 3 months and treatment was well tolerated.

Eligible patients will have histologically confirmed Multiple Myeloma (MM) having not received prior systemic therapy given with the intent to induce remission, be adults, have life expectancy greater than 3 months, adequate performance status, organ and marrow function as described in the protocol, not be pregnant, HIV positive, or taking any investigational agents. Patients must not have history of allergic reactions to study drugs or similar compounds or have uncontrolled intercurrent illness or social situation that would limit compliance with study requirements. Patients must also have the ability to give informed consent.

Study drugs will be administered on an inpatient or outpatient basis. Bortezomib 1.3 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 4, 8, and 11 of a 28 day cycle. Six cycles are planned. On days when both melphalan and bortezomib are given, melphalan is given at least one hour prior to bortezomib. Melphalan 6 mg/m2 is administered orally on an empty stomach daily on days 1-7 of each cycle. Prednisone 60 mg/m2 is administered orally daily on days 1-7 of each cycle. Supportive care measures such as antiemetics and growth factors may be given.
The invention provides a serial double-medicine link assembly unit and application thereof. The serial double-drug link assembly unit is shown as a formula I. According to the invention, the specific link assembly units are used for connecting the targeting DNA and the microtubulin small molecular compound to the same antibody in a serial connection manner, and the anti-tumor effect is exerted through two different action mechanisms, so that the drug resistance generated by single-target tumor treatment is overcome. At the same time, drugs that combine two different mechanisms of action of anticancer can provide complementary activity against tumors, yielding ADCs with enhanced antitumor activity. The connection method provided by the invention is suitable for most antibodies, so that the complicated recombination modification of each antibody to introduce a site-specific coupling site can be avoided, and the method has a very wide application prospect. L-D1-T-D2 is formula I.
In a method for triggering an action of a device (for example, outputting a medicine package) authorised by a paper document (e.g. a prescription), wherein the action requires a unique assignment of a signature to the paper document, initially at a first location at which the action is to be executed, the paper document is placed in a receptacle, an application device permanently applies a first unique identifier to the paper document (e.g. printed) and generates an electronic image of the paper document, wherein a second identifier is uniquely assigned to the first identifier, and an electronic document is generated from the electronic image and is linked to the second identifier. An image of the electronic document is then displayed to a second, remote location of a person authorised to sign (e.g. pharmacist) and the electronic document is signed by the authorised person by means of a predefined entry into an input device. The electronic document, which is linked to the second identifier and signed, is then stored in a secure memory. Once this process is complete, the authorised action is executed by the device.
The investigators plan to measure blood pressure (BP) in 30 consecutive individuals presenting to the St. Elizabeth Boardman Family Health Center. The sample will include patients presenting for their scheduled appointment. Following informed consent (see attached informed consent form), the participants will be randomly assigned to one of two groups. In group A, the sequence of BP measurements will be table position (TP) followed by recommended chair position (RCP) and then, after a 30-minutes rest, the BP will be measured again in the reverse sequence, RCP then TP. In group B, the sequence will begin with BP measurements in the RCP then TP, followed by 30-minutes rest and then measurements will be repeated in the reverse order. The assignment of participants to groups A and B will be random. The BP will be measured twice in each of the positions described above, according the the accepted standard technique, using a digital blood pressure monitor, the OMRON HEM-907 XL.
Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 600 μg bid group includes all patients whose mean daily dose \< 1500 μg /day.
Disclosed are a method of producing a salt containing a fermented extract of a medicinal herb, and a use of the salt containing a fermented extract of a medicinal herb. Specifically, 0.01-95 parts by weight of beneficial bacteria and 1-50 parts by weight of a medicinal herb showing a scalp treatment effect, with respect to the total weight of a diluted sugar solution whose sugar content has been adjusted to about 0.1-30 brix, are mixed and fermented at 10-60C for one day to two years, and filtered to produce a fermented extract of a medicinal herb. Further, the fermented extract of a medicinal herb is mixed with salt in a ratio of 1 : 0.1-10, and dried at 60C or less in a dryer to produce a salt containing a fermented extract of a medicinal herb. The salt containing a fermented extract of a medicinal herb produced above may be provided to produce scalp treatment compositions in various forms including liniment, shampoo, liquid soap, solid soap, a powder cleanser, and a gel agent. According to the present invention, the salt containing a fermented extract of a medicinal herb produced by the method of the present invention can be stored for a long time without degradation, and are easy to handle. Accordingly, the salt containing a fermented extract of a medicinal herb having a scalp treatment effect may be used as a material for scalp treatment compositions that allows a consumer to produce scalp treatment compositions containing the salt containing a fermented extract of a medicinal herb at home inexpensively, such as liniment, shampoo, liquid soap, solid soap, a powder cleanser, and a gel agent, by adding the salt containing a fermented extract of a medicinal herb to the compositions.
This pilot study is a single-center, two-arm randomized study that by design is unblinded. 200 total participants are planned. Each participant will be randomized in an unblocked manner to receive "usual care" or the ECA/KAC intervention. Participants will have study visits at baseline and time 30 days. Adherence to using the ECA/KAC in combination over 30 days will be quantified. Following participation study participants randomized to the ECA/KAC intervention will undergo an interview to determine their experience with the ECA/KAC. Participants and their physicians will receive a summary of ECA use and symptoms and correlated findings by KAC.
Sepsis is today a major cause of morbidity and mortality worldwide. Septic shock, the most serious manifestation of the infection, affects 2 to 20% of intensive care patients. Despite appropriate antibiotic therapy and improved resuscitation strategies based on early treatment, volume expansion and rational use of vasopressors, the mortality rate of shock states remains too high, between 40 and 50%.

Over the past two decades, great advances have been made in the understanding the pathophysiology of septic shock. Microcirculatory abnormalities have been identified as the main cause of organ hypoperfusion and visceral failure leading to death. In addition, several studies in animals and humans have highlighted a discordance between systemic hemodynamic parameters and alterations of small vessels during shock suggesting that microvascular blood flow and tissue perfusion should be analyzed in patients with acute circulatory failure in association with blood pressure and cardiac output. Capillary refill time (CRT), is an easy-to-use, easy-to learn tool to evaluate peripheral tissue perfusion. CRT is a strong predictive factor of organ failure severity and poor outcome in critically ill patients with sepsis. A recent randomized trial reported promising results regarding the use of CRT to guide resuscitation. However, little is known about the impact of treatment on CRT. The aim of this work is to study the kinetics of CRT and local skin blood flow following therapeutic intervention (fluid challenge, vasopressor or inotropic drug).
Noncoding RNAs (ncRNAs), including long noncoding RNAs (lncRNAs) and microRNAs (miRNAs), play crucial roles in gene expression regulation and are significant in disease associations and medical research. Accurate ncRNA-disease association prediction is essential for understanding disease mechanisms and developing treatments. Existing methods often focus on single tasks like lncRNA-disease associations (LDAs), miRNA-disease associations (MDAs), or lncRNA-miRNA interactions (LMIs), and fail to exploit heterogeneous graph characteristics. We propose ACLNDA, an asymmetric graph contrastive learning framework for analyzing heterophilic ncRNA-disease associations. It constructs inter-layer adjacency matrices from the original lncRNA, miRNA, and disease associations, and uses a Top-K intra-layer similarity edges construction approach to form a triple-layer heterogeneous graph. Unlike traditional works, to account for both node attribute features (ncRNA/disease) and node preference features (association), ACLNDA employs an asymmetric yet simple graph contrastive learning framework to maximize one-hop neighborhood context and two-hop similarity, extracting ncRNA-disease features without relying on graph augmentations or homophily assumptions, reducing computational cost while preserving data integrity. Our framework is capable of being applied to a universal range of potential LDA, MDA, and LMI association predictions. Further experimental results demonstrate superior performance to other existing state-of-the-art baseline methods, which shows its potential for providing insights into disease diagnosis and therapeutic target identification. The source code and data of ACLNDA is publicly available at https://github.com/AI4Bread/ACLNDA.